아일리아 시장 : 치료 클래스, 투여 방법, 환자 유형, 최종사용자별 - 세계 예측(2025-2030년)

The Eylea Market was valued at USD 6.89 billion in 2023, expected to reach USD 7.25 billion in 2024, and is projected to grow at a CAGR of 6.83%, to USD 10.95 billion by 2030.

Eylea (aflibercept) operates within the ophthalmology pharmaceutical market, primarily focusing on treating retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Its necessity stems from the demand for effective therapies that address the significant unmet need for managing vision impairment in the aging global population and among diabetic patients. Applied as an injectable treatment, Eylea has gained trust due to its proven efficacy and safety profile, contributing to its widespread acceptance and application primarily among ophthalmologists. The end-use scope encompasses clinics, hospitals, and ambulatory service centers where such treatments are administered. Key growth factors influencing this market include a growing incidence of retinal diseases, continuous advancements in drug formulations, and expanding awareness about eye health. Recent potential opportunities include its further inclusion in combination therapies and expanding indications to capture wider markets. This could be achieved through strategic research partnerships and clinical trials, aiming to enhance efficacy and reduce side effects. However, market growth faces limitations such as high treatment costs, stringent regulatory scenarios, and increasing competition from biosimilars and alternative therapies which may affect pricing and market share. The best areas for innovation include enhancing delivery mechanisms, like sustained-release formulations, to improve patient convenience and compliance. Another promising area is the use of artificial intelligence and machine learning to improve diagnostic accuracy and treatment personalization. The market's nature is dynamic, driven by scientific advancements and competitive pressures that necessitate continuous adaptation. For businesses, focusing on capturing emerging markets with lower competition and creating strategic alliances with hospitals and healthcare providers can position them favorably. Moreover, investing in educational marketing campaigns can boost market penetration by raising awareness of Eylea's benefits among healthcare providers and patients alike.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Eylea Market

The Eylea Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Expansion of healthcare infrastructure in emerging economies enhancing accessibility to Eylea treatments
  • Collaborations and partnerships among pharmaceutical companies accelerating development and distribution of Eylea
  • Growing elderly population globally contributing to higher incidence of retinal disorders treatable by Eylea
  • Increased investment in research and development activities for innovative ophthalmic solutions supporting Eylea market growth
• Market Restraints
  • Limited patient accessibility and affordability of advanced anti-VEGF therapies
  • Increasing competition from emerging biosimilars reducing market share of established brands
• Market Opportunities
  • Developing patient education programs to enhance understanding of retinal disease management
  • Leveraging big data analytics for early detection and monitoring of retinal conditions
  • Promoting home-based care solutions to increase patient convenience and adherence
• Market Challenges
  • Competition from alternative treatment options for retinal diseases impacting Eylea's market share
  • Regulatory and compliance challenges affecting the marketing and distribution of Eylea in different regions

Porter's Five Forces: A Strategic Tool for Navigating the Eylea Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Eylea Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Eylea Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Eylea Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Eylea Market

A detailed market share analysis in the Eylea Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Eylea Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Eylea Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Eylea Market

A strategic analysis of the Eylea Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Eylea Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Alexion Pharmaceuticals, Inc., Allergan, Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Eylea Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutic Class, market is studied across Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Disorders.
• Based on Mode Of Administration, market is studied across Intravitreal Injection and Ocular Implants. The Ocular Implants is further studied across Biodegradable and Non-Biodegradable.
• Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Expansion of healthcare infrastructure in emerging economies enhancing accessibility to Eylea treatments
    • 5.1.1.2. Collaborations and partnerships among pharmaceutical companies accelerating development and distribution of Eylea
    • 5.1.1.3. Growing elderly population globally contributing to higher incidence of retinal disorders treatable by Eylea
    • 5.1.1.4. Increased investment in research and development activities for innovative ophthalmic solutions supporting Eylea market growth
  • 5.1.2. Restraints
    • 5.1.2.1. Limited patient accessibility and affordability of advanced anti-VEGF therapies
    • 5.1.2.2. Increasing competition from emerging biosimilars reducing market share of established brands
  • 5.1.3. Opportunities
    • 5.1.3.1. Developing patient education programs to enhance understanding of retinal disease management
    • 5.1.3.2. Leveraging big data analytics for early detection and monitoring of retinal conditions
    • 5.1.3.3. Promoting home-based care solutions to increase patient convenience and adherence
  • 5.1.4. Challenges
    • 5.1.4.1. Competition from alternative treatment options for retinal diseases impacting Eylea's market share
    • 5.1.4.2. Regulatory and compliance challenges affecting the marketing and distribution of Eylea in different regions
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Eylea Market, by Therapeutic Class

• 6.1. Introduction
• 6.2. Age-Related Macular Degeneration
• 6.3. Diabetic Macular Edema
• 6.4. Retinal Disorders

7. Eylea Market, by Mode Of Administration

• 7.1. Introduction
• 7.2. Intravitreal Injection
• 7.3. Ocular Implants
  • 7.3.1. Biodegradable
  • 7.3.2. Non-Biodegradable

8. Eylea Market, by Patient Type

• 8.1. Introduction
• 8.2. Adult
• 8.3. Geriatric
• 8.4. Pediatric

9. Eylea Market, by End-User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals
• 9.4. Ophthalmic Clinics

10. Americas Eylea Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Eylea Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Eylea Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alcon Inc.
• 3. Alexion Pharmaceuticals, Inc.
• 4. Allergan, Inc.
• 5. Amgen Inc.
• 6. Astellas Pharma Inc.
• 7. Bayer AG
• 8. Biogen Inc.
• 9. Bristol-Myers Squibb Company
• 10. Eli Lilly and Company
• 11. Genentech, Inc.
• 12. GlaxoSmithKline plc
• 13. Johnson & Johnson
• 14. Merck & Co., Inc.
• 15. Novartis International AG
• 16. Pfizer Inc.
• 17. Regeneron Pharmaceuticals, Inc.
• 18. Roche Holding AG
• 19. Sanofi S.A.
• 20. Teva Pharmaceutical Industries Ltd.